For persistent arthritis after checkpoint inhibitor cessation, DMARDs don’t seem to blunt tumor response. Increasing issue given the number of patients on combo therapy at risk of arthritis persistence post-ICI cessation. Congratulations @cappelliMD &Dr Braaten!!
#ACR19 @RheumNow https://t.co/C3N13D3Dqm https://t.co/H66bnMGGkL
Links:
Laura Cappelli on Twitter: "So proud of Tawnie Braaten for her hard work i…
https://twitter.com/cappellimd/status/1193987163769180160
Nov-11-2019
